A Phase II Study of Induction Tucatinib and Trastuzumab With Total Neoadjuvant Therapy for Locally Advanced HER2-amplified Rectal Adenocarcinoma
Latest Information Update: 26 Dec 2024
At a glance
- Drugs Trastuzumab (Primary) ; Tucatinib (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Adenocarcinoma; Rectal cancer
- Focus Therapeutic Use
Most Recent Events
- 12 Apr 2024 Chemotherapy CAPOX is replaced by FOLFOX.
- 06 Jan 2023 New trial record